Latest news
Capricor seeks court intervention in fight over DMD cell therapy launch - FirstWord PharmaFirstWord Pharma · Wed, 05 Aug 2026 07:00:00 GMTCapricor’s Duchenne AdCom Didn’t Fail on Science. It Failed on Statistics. - The Clinical Trial VanguardThe Clinical Trial Vanguard · Tue, 04 Aug 2026 07:38:27 GMTStockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel - Genetic Engineering and Biotechnology NewsGenetic Engineering and Biotechnology News · Mon, 03 Aug 2026 00:49:26 GMTFDA advisory panel votes against Capricor's Duchenne cell therapy deramiocel - DealroomDealroom · Thu, 30 Jul 2026 22:39:44 GMTFDA AdCom shuns Capricor’s DMD cell therapy amid data dispute - Pharmaceutical TechnologyPharmaceutical Technology · Thu, 30 Jul 2026 14:06:52 GMTDuchenne Therapy Has Aug. 22 FDA Action Target After Panel Vote - Stock TitanStock Titan · Thu, 30 Jul 2026 13:30:00 GMTFDA advisors vote no to Capricor's DMD therapy - pharmaphorumpharmaphorum · Thu, 30 Jul 2026 09:10:40 GMTFDA Advisory Panel Votes Against Approval of Deramiocel for DMD - The American Journal of Managed Care® (AJMC®)The American Journal of Managed Care® (AJMC®) · Thu, 30 Jul 2026 07:00:00 GMT